Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Status:
Active, not recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the
effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent
or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian
tube, or primary peritoneal cancer. Its primary objective is to assess whether adding
bevacizumab to ixabepilone improves progression-free survival in its target population. Study
participants will be stratified by (a) study site and (b) previous receipt of bevacizumab
prior to randomization.